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THE IMPACT OF THE IPLEDGE PROGRAM ON ISOTRETINOIN FETAL 
EXPOSURE
Shin J1, Niu F2, Wong L3, Yoshinaga MA2, McCombs J1, Cheetham CT2
1USC School of Pharmacy, Los Angeles, CA, USA, 2Kaiser Permanente, Downey, CA, USA, 
3Kaiser Permanente, City of Industry, CA, USA
OBJECTIVES: The objective of this retrospective cohort study is to analyze the effect 
of the iPLEDGE program on rates of fetal exposure to isotretinoin in females of child-
bearing potential (FCBP). METHODS: This study used databases from Kaiser Perma-
nente Southern California, which includes prescription records, laboratory results, and 
outpatient/inpatient visit procedures and diagnoses. All FCBP who ﬁlled isotretinoin 
during the study period of March 1, 2004 to February 29, 2008 were identiﬁed. Chart 
review was performed to validate pregnancy in patients with positive pregnancy 
indicators. The analysis was performed at the treatment course-level. Treatment 
courses were excluded if they straddled both before and after iPLEDGE implementa-
tion on March 1, 2006. Poisson regression was used to analyze the impact of iPLEDGE 
on the rate of fetal exposures, controlling for age, prior utilization of acne prescription 
medications, and other risk factors. RESULTS: There were a total of 8 fetal exposures 
during 2585 treatment courses before iPLEDGE and 6 fetal exposures during 1595 
treatment courses after iPLEDGE implementation. Unadjusted fetal exposure rates 
increased slightly from 3.09 per 1000 treatment courses to 3.76 per 1000 treatment 
courses with iPLEDGE. When controlling for other factors, the rate ratio for fetal 
exposure after compared to before iPLEDGE implementation was 0.45 [95%CI: 0.31, 
0.67] in FCBP less than 21 years of age. In FCBP greater than or equal to 21 years 
of age, the rate ratio was 1.46 [95%CI: 1.10, 1.94]. CONCLUSIONS: The risk of 
fetal exposure among treatment courses ﬁlled by younger FCBP signiﬁcantly decreased 
by 55% after the implementation of iPLEDGE. In contrast, the risk of fetal exposure 
signiﬁcantly increased by 46% after iPLEDGE began among treatment courses ﬁlled 
by older FCBP. Our results suggest that the iPLEDGE program had a differential effect 
on the rate of fetal exposures to isotretinoin depending on patient age group.
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DEVELOPMENT OF A DECISION-ANALYTIC MODEL FOR GLAUCOMA 
PROGRESSION USING PATIENT LEVEL DATA FROM THREE LARGE 
RANDOMIZED CONTROLLED TRIALS
Kymes S1, Kotak S2, Lambert D1, Stwalley D1, Siegfried C1, Lee PP3, Musch D4, Fain J5, 
Gordon M1
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University, Durham, NC, USA, 4University of Michigan, Ann Arbor, MI, USA, 5Pﬁzer, Inc., 
Chicago, IL, USA
OBJECTIVES: Evaluation of cost-effectiveness for chronic disease treatment requires 
development and validation of a model of disease progression using “real world” data. 
We constructed a Markov model using patient-level data from three large studies of 
glaucoma treatment and conducted internal validation. METHODS: Glaucoma sever-
ity and disease progression were deﬁned clinically in terms of visual ﬁeld loss expressed 
as mean deviation (MD) measured in decibels (dB). Patient level data for the model 
came from the Collaborative Initial Glaucoma Treatment Study (CIGTS n = 574), the 
Ocular Hypertension Treatment Study (OHTS n = 1,546), and the Advanced Glau-
coma Intervention Study (AGIS n = 580). Our initial model was limited to the pattern 
of progression over seven years. Transition probabilities for the Markov model were 
calculated for each combination of year and MD. The model was estimated with 
TreeAge software using a microsimulation approach. Internal validation was con-
ducted by comparing the predicted value of hypothetical participants to that of the 
actual study participants. For this purpose, a clinically signiﬁcant difference was 
considered to be 3 decibels (dB) of MD. RESULTS: Three variables—age, race, and 
starting MD—were most strongly associated with change in MD. Predicted values 
from the model were regressed on actual study results. The R2 for the right eye was 
0.72, and for the left 0.70. Of those participants outside of a 3 dB band around 
“perfect” prediction, over 85% had less severe disease at year 7 than predicted by the 
model. CONCLUSIONS: Our initial results indicate that the glaucoma progression 
model properly predicts the result of disease progression in over 80% of “partici-
pants”. This suggests that our modeling approach provides a reasonable reﬂection of 
real world progression and provides a useful tool for researchers and policy makers. 
Once completed, this model will provide a tool for evaluation of pressure lowering 
medications.
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CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies
PCV1
EFFECT OF BIVALIRUDIN ON CLINICAL OUTCOMES OF STEMI 
PATIENTS IN AN OBSERVATIONAL DATASET
Kessler DP
Stanford University, Stanford, CA, USA
OBJECTIVES: Hospitals are increasingly focused on reducing patient harm associated 
with anticoagulant therapy. However, because treatment decisions may be based on 
prognosis, estimates of treatment effects obtained from observational data may suffer 
from “confounding by indication.” To address this concern, we used a grouped-
treatment approach to determine the impact of choice of anticoagulant on the risk of 
severe bleeding and in-hospital death in patients undergoing percutaneous coronary 
intervention (PCI). METHODS: We analyzed the Premier Perspective database on 
patients aged ≥18 years admitted to Premier hospitals with a diagnosis of ST-elevated 
myocardial infarction (STEMI) and ≥1 procedure code for PCI between Q12004 and 
Q12008 (N = 71,296). We constructed individual-level models of severe bleeding and 
in-hospital death (all-cause) similar to those in a conventional multivariate analysis, 
except that each individual’s actual treatment variables were replaced with grouped-
treatment variables (the proportion of patients receiving each treatment at the hospital/
year in which treatment occurred). We used logistic regression to assess the impact of 
the likelihood of treatment with bivalirudin or heparin ± a glycoprotein IIb/IIIa inhibi-
tor on severe bleeding and in-hospital death, controlling for other treatments (includ-
ing stent use, other drug use, CABG); patient demographics, concomitant diagnoses, 
insurance status, physician specialty; and hospital region, size, teaching status. We 
calculated conﬁdence intervals allowing for the clustering of errors at the hospital/year 
level. RESULTS: Bivalirudin treatment was associated with a signiﬁcantly reduced risk 
of severe bleeding (OR = 0.45, 95% CI = 0.21–0.97) and a reduced risk of in-hospital 
mortality (OR = 0.83, 95% CI 0.54–1.28) compared to heparin+GPI. CONCLU-
SIONS: Increasing the proportion of a hospital’s patients treated with bivalirudin was 
associated with a signiﬁcant reduction in severe bleeding. These results demonstrate 
the beneﬁts of bivalirudin for clinical outcomes in a real-world setting.
PCV2
POSTMARKETING SAFETY EVALUATION OF ALISKIREN 
HEMIFUMARATE, A NEW MOLECULAR ENTITY
Ali AK
University of Florida, Gainesville, FL, USA
OBJECTIVES: To evaluate the safety proﬁle of aliskiren by calculating the adjusted 
reporting ratios of speciﬁc adverse events. METHODS: The FDA’s Adverse Event 
Reporting System (AERS) data are utilized to conduct this retrospective pharmaco-
vigilance study. Adverse event (AE) reports submitted to the AERS during the period 
of January 2007 through December 2008 are included in the analysis. Systematic 
Multi-item Gamma Poisson Shrinker (MGPS) data mining algorithm is applied to 
calculate the adjusted reporting ratios (ARR) of AE, which estimated by the Empiric 
Bayes Geometric Mean (EBGM) values and their 95% conﬁdence intervals (95%CI). 
EBGM values of >2.0 are considered as safety signals signiﬁcant for regulatory deci-
sions. Reports for aliskiren and other drugs affecting the Renin-Angiotensin-Aldoste-
rone System (RAAS) are identiﬁed using the verbatim names for each individual class 
members. Reports for speciﬁc AE are identiﬁed by the utilized Preferred Terms of the 
Medical Dictionary for Regulatory Activities coding scheme (MedDRA PT) in the 
AERS. RESULTS: During the study period, a total number of 2154 reports for aliski-
ren are received by the AERS. Seventy four percent (1592) of these reports had valid 
MedDRA terms, and included in the analysis. Compared to other RAAS modulators, 
aliskiren was associated with the highest ARR for angioedema (EBGM 3.9, 95%CI 
3.2–4.7), renal dysfunction (EBGM 3.4, 95%CI 2.6–4.5), dry cough (EBGM 11.0, 
95%CI 7.8–14.2), and diarrhoea (EBGM 4.3, 95%CI 3.2–5.8). Aliskiren ranked the 
second after aldosterone antagonists in hyperkalaemia (EBGM 7.4, 95%CI 3.4–13.0). 
CONCLUSIONS: Treatment with aliskiren may be associated with angioedema and 
renal dysfunction. Patients with signs and symptoms of angioedema should stop 
aliskiren and seek urgent medical help. Aliskiren should not be used by patients with 
risks of renal dysfunction. While additional longitudinal studies and clinical awareness 
is warranted, regulatory changes in product label and safety communications, e.g. 
dear-health care-professional letters are recommended.
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ESTIMATION OF ADVERSE EVENTS RELATED WITH MEDICARE 
PATIENTS WHO UNDERWENT HIP FRACTURE SURGERY AND 
SUFFERED VENOUS THROMBOEMBOLISM VERSUS NO VENOUS 
THROMBOEMBOLISM
Wang L1, Dysinger A1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research / University of 
Michigan, Ann Arbor, MI, USA
OBJECTIVES: To estimate mortality, re-hospitalization and bleeding 30 days after a 
venous thromboembolism (VTE) event in patients following hip fracture surgery and 
to compare the outcomes with patients without VTE. METHODS: Based on 2005–
2007 national Medicare claims, all patients who underwent hip fracture surgery were 
identiﬁed. Thirty days follow-up event rates for patients who had a VTE event during 
their initial hospitalization were calculated. Events were compared between patients 
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who suffered a VTE event and those that did not. Risk adjustment was done using 
propensity score matching (using the ProbChoiceTM algorithm) controlling for baseline 
demographic and clinical characteristics between patients with and without VTE. 
RESULTS: In patients who underwent hip fracture surgery (n = 104,952), 1.9% had 
post-operative VTE events during their initial hospitalization. Almost 69% (n = 1377) 
of these patients suffered deep vein thrombosis (DVT), 25% (n = 501) had a pulmo-
nary embolism (PE), and 6% (n = 119) had both DVT and PE. After multivariate 
adjustment for pre-speciﬁed covariates, mortality was almost 50% higher for patients 
with VTE compared to those without VTE. Differences in mortality rate were more 
pronounced for PE patients, whom the event was associated with almost two-fold. 
The VTE group was more likely to be re-hospitalized in one year (odds ratio: 1.44, p 
= 0.02). Bleeding was 2.26 times higher (p = 0.000). CONCLUSIONS: VTE events 
during initial hospitalization for hip fracture surgery increased the mortality, re-hos-
pitalization and bleeding compared with no VTE events.
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COMPARISON OF MORTALITY, RE-HOSPITALIZATION AND BLEEDING 
RATES OF MEDICARE PATIENTS WHO UNDERWENT KNEE 
REPLACEMENT SURGERY AND SUFFERED VENOUS 
THROMBOEMBOLISM VERSUS NO VENOUS THROMBOEMBOLISM
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OBJECTIVES: To estimate re-hospitalization and bleeding rates during the 90 days 
after a venous thromboembolism (VTE) event in patients who underwent knee replace-
ment surgery and to compare the outcomes with patients who did not suffer 
VTE. METHODS: Based on 2005–2007 national Medicare claims, all patients who 
underwent knee replacement surgery were identiﬁed. The 90 days follow-up event rates 
for patients who had a VTE event during their initial hospitalization were calculated. 
Events were compared between patients who suffered a VTE event and those who did 
not. Risk adjustment was done using propensity score matching (using the ProbChoi-
ceTM algorithm) controlling for baseline demographic and clinical characteristics 
between patients with and without VTE. RESULTS: In patients who underwent total 
knee replacement surgery (n = 104,952), 1.9% had post-operative VTE events during 
their initial hospitalization. Almost 69% (n = 1377) of these patients had deep vein 
thrombosis (DVT), 25% (n = 501) had pulmonary embolism (PE), and 6% (n = 119) 
had both DVT and PE. The overall likelihood of mortality was four times higher for 
VTE patients versus those without VTE (1.35% vs. 0.35%). Patients with VTE during 
their initial hospitalization were more likely to be hospitalized in 90 days (compared to 
patients without an event during the same hospital stay (16.62% vs. 8.00%). In 90 days 
after the event, patients with VTE were more likely to have bleeding (10.17% vs. 
2.68%). CONCLUSIONS: VTE events during initial hospitalization for total knee 
replacement surgery increased the adverse events compared with no VTE events.
PCV5
ADVERSE EVENT ANALYSIS FOR MEDICARE PATIENTS WHO 
UNDERWENT HIP FRACTURE SURGERY AND SUFFERED VENOUS 
THROMBOEMBOLISM
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OBJECTIVES: To estimate re-hospitalization and bleeding during the 30 days after a 
venous thromboembolism (VTE) event in patients following hip fracture surgery and 
to compare the outcomes with patients without VTE. METHODS: Based on 2005–
2007 national Medicare claims, all patients who underwent hip fracture surgery were 
identiﬁed. The 30 days follow-up event rates for patients who had a VTE event during 
their initial hospitalization were calculated. Events were compared between patients 
who suffered a VTE event and those who did not. Risk adjustment was done using 
propensity score matching controlling for baseline demographic and clinical charac-
teristics between patients with and without VTE. RESULTS: In patients who under-
went hip fracture surgery (n = 50,245), 1.5% had post-operative VTE during their 
initial hospitalization. Almost 77% (n = 573) of these patients had deep vein throm-
bosis (DVT), 20% (n = 141) had a pulmonary embolism (PE), and 3% (n = 34) had 
both DVT and PE. Patients with VTE during their initial hospitalization were more 
likely to be hospitalized in 30 days (compared to patients without an event during the 
same hospital stay (32% vs. 6.82%). In 30 days after the event, patients with VTE 
were more likely to have bleeding (10.65% vs. 0.68%). CONCLUSIONS: VTE events 
during initial hospitalization for hip fracture surgery patients increased the adverse 
events compared with no VTE events.
PCV6
A META-ANALYSIS OF EFFICACY OF ATORVASTATIN IN COMPARISON 
TO PRAVASTATIN, SIMVASTATIN AND ROSUVASTATIN FOR THE 
CONTROL OF DYSLIPIDEMIA AND CARDIOVASCULAR EVENTS 
PREVENTION
Villasis-Keever MA1, Rendón-Masías ME1, Pineda-Cruz R1, Escamilla-Nuñez A1, 
Mould-Quevedo JF2
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OBJECTIVES: The aim of this study was to conduct a meta-analysis of randomized 
clinical trials (RCTs) to identify the effectiveness and safety of atorvastatina 
(20 mg–80 mg) against pravastatin, simvastatin and rosuvastatin. METHODS: A 
systematic review was performed including RCTs in primary and secondary preven-
tion where total cholesterol, LDL-C, HDL-C, major cardiovascular events, as well as 
adverse events frequency werw analyzed. RCTs were searched in March 2009 in 
Medline, EMBASE and the Cochrane Collaboration. Two independent reviewers 
identiﬁed the abstracts, selected the full articles, and extracted the data. Odds ratios 
(OR) and weighted means differences were calculated with 95% conﬁdence intervals 
(95%CI). Random effects models were employed in the Meta-analyses using RevMan 
v.5.0 software. RESULTS: From 7539 studies, 66 RCT were selected. Atorvastatin 
showed statistically a higher improvements in LDL-C, total cholesterol, HDL-C and 
triglycerides in comparison to pravastatin and simvastatin (5%–15%). Rosuvastatin 
was statistically superior against atorvastatin in LDL-C and total cholesterol, however 
not in HDL-C and triglycerides (p < 0.01). Atorvastatin obtained higher reductions 
in acute myocardial infarctions (AMI), unstable angina, and revascularizations in 
comparison to pravastatin and simvastatin (p < 0.05). Atorvastatin 80 mg showed in 
comparison to pravastatin 40 mg a higher reduction of mayor cardiovascular events 
(OR 0.87; 95%CI 0.77–0.97, p = 0.01), revascularization (OR 0.86; IC95% 0.76–
0.98, p = 0.02) and unstable angina (OR 0.74; 95%CI 0.57–0.95, p = 0.02); neverthe-
less no statistical differences were found for AMI or cardiovascular death. Rosuvastatin 
requires data on cardiovascular events prevention in order to be compare appropri-
ately against atorvastatin. The frequency of adverse events resulted similar among all 
the statins considered in the assessment. CONCLUSIONS: Atorvastatin in comparison 
to pravastatin and simvastatin showed a higher control of dyslipidemia and a better 
reduction of major cardiovascular events, without increasing the frequency of adverse 
events.
PCV7
INCIDENCE AND OUTCOMES OF POTENTIAL DRUG-DRUG 
INTERACTIONS BETWEEN ACE/ARB AND POTASIUM SPARING 
DIURETICS
Banahan III BF, Mendonca CM, Athavale A, Bentley JP
University of Mississippi, Oxford, MS, USA
OBJECTIVES: To examine incidence of and the health outcomes associated with 
potential drug-drug interactions (DDIs) between ACE/ARBs and potassium sparing 
diuretics among Medicaid patients. METHODS: A retrospective matched cohort study 
was conducted of beneﬁciaries in the Mississippi Medicaid program from January 
2002 to December 2004. Potential DDIs were deﬁned as medication possession data 
indicating an object drug (ACE/ARB) and a precipitant drug (potassium sparing 
diuretic) were taken with overlapping dates. The ﬁrst day of overlap was designated 
as the DDI index date. A 6-month washout period was used for exposures. Exposed 
patients were matched 1-1 to controls taking ACE/ARBs and assigned the same index 
date. Exact matching was done on sex, race, CHF comorbidity, and cerobrovascular 
disease comorbidity and close matching was done for age (±10) and ﬁrst use date for 
ACE/ARB (±45). Outcomes included hospitalizations and ER visits within 30 days of 
the index date and payments associated with these services. RESULTS: A total of 
68,299 patients were identiﬁed as taking ACE/ARBs during the observation period 
with 5572 (8.4%) exposed to a potential DDI. A total of 5599 exposed patients were 
matched. The effect of DDI exposure on hospitalization and ER visit rates was tested 
using SAS ﬁxed effects logistical regression while controlling for sex, age, race and 
overall Charlson comorbidity index. The point-speciﬁc odds ratio for DDI exposure 
was 1.41 (95% CI = 1.29 − 1.54) for hospitalization and 1.21 (95% CI = 1.11 − 1.31) 
for ER visits. A paired t-test was used to examine differences in Medicaid payments 
during the 30-days after the index date. Total payments were signiﬁcantly higher (p 
< 0.001) for the exposed patients ($2289) than for the control patients ($1,614). 
CONCLUSIONS: Potential ACE/ARB DDIs were a signiﬁcant problem among the 
Mississippi Medicaid patients and during the study period; potentially contributing 
more than $3.7M in additional health care costs.
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CLINICAL RELEVANCE OF PHARMACOLOGICAL INTERACTIONS
Endel G1, Neumann K2
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OBJECTIVES: Adverse events –Aes—due to medication errors are numerous. One 
type of error is the combination of substances with a known unwanted pharmacologi-
cal interaction. In the years 2001 to 2006 a total of 39521 AEs with ICD10 codes 
indicating drugs as reason where documented in Austrias hospitals. There is no report-
ing system or documentation for adverse events in ambulatory care. So the rate of 
AEs in the outpatient setting is unknown. One of the main projects in Austrias e-health 
roadmap is an e-medication system. Due to the foreseeable costs an estimation and 
calculation of potential beneﬁts is mandatory. METHODS: We use reimbursement 
data of the Austrian social insurance companies covering the years 2006 and 2007. 
The domains included are pharmaceutical reimbursement, reimbursement of outpa-
tient medical services, hospital reimbursement data and sick leave data. We focus on 
interactions between the following pharmaceutical groups: 1. ATC code C10AA—
statins, 2. ATC code N5BA—benzodiacepins, 3. ATC code J01FA makrolide antibiot-
ics and 4. ATC code C01BD amiodarone. RESULTS: The main question to answer 
is the prevalence and incidence of such interaction patterns. This will lead to a descrip-
tion of the epidemiology of potential AEs which can at least be qualiﬁed as medical 
errors. The second question is the frequency of clinical relevant interactions. A clinical 
(and economic) relevance is ascertained, if the interaction needs medical treatment. 
The detection of outcomes of an interaction is the main challenge. CONCLUSIONS: 
The extent to which an e-medication system can improve patient safety can be esti-
